Literature DB >> 19302551

Role of 20-hydroxyeicosatetraenoic acid in altering vascular reactivity in diabetes.

M H M Yousif1, I F Benter, K M J Dunn, A J Dahly-Vernon, S Akhtar, R J Roman.   

Abstract

1 This study examined the role of 20-hydroxyeicosatetraenoic (20-HETE) in altering vascular function in streptozotocin (STZ)-induced diabetic rats. 2 The expression of CYP4A protein and the formation of 20-HETE were elevated in the kidney, but not in the renal or mesenteric vasculature, of diabetic animals. The vasoconstrictor responses to norepinephrine (NE), endothelin-1 (ET-1), and angiotensin II (Ang II) were significantly enhanced in the isolated perfused mesenteric vascular bed and renal artery segments of diabetic rats. Chronic treatment of the diabetic rats with 1-aminobenzotriazole (ABT, 50 mg kg(-1) alt(-1) diem) or N-hydroxy-N'-(4-butyl-2-methylphenyl) formamidine (HET0016, 2.5 mg kg(-1) day(-1)) attenuated the responses to these vasoconstrictors in both vascular beds. 3 The synthesis of 20-HETE in renal microsomes was reduced by >80% confirming that the doses of ABT and HET0016 were sufficient to achieve system blockade. Addition of HET0016 (1 microM) in vitro also normalized the enhanced vascular responsiveness of renal and mesenteric vessels obtained from diabetic animals to NE and inhibited the formation of 20-HETE by >90% while having no effect on the formation of epoxides. Vasodilator responses to carbachol and histamine were reduced in the mesenteric vasculature, but not in renal arteries, of diabetic rats. Treatment of the diabetic animals with HET0016 improved vasodilator responses in both vascular beds. Vascular sensitivity to exogenous 20-HETE was elevated in the mesenteric bed of diabetic animals compared to controls. 4 These results suggest that 20-HETE contributes to the elevation in vascular reactivity in diabetic animals. This effect is not due to increased vascular expression of CYP4A but may be related to either enhanced agonist-induced release of substrate (arachidonic acid) by the CaMKII/Ras-GTPase system and/or elevated vascular responsiveness to 20-HETE by the CaMKII/Ras-GTPase system and/or elevated vascular responsiveness to 20-HETE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302551      PMCID: PMC2831294          DOI: 10.1111/j.1474-8673.2009.00426.x

Source DB:  PubMed          Journal:  Auton Autacoid Pharmacol        ISSN: 1474-8665


  46 in total

1.  HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme.

Authors:  N Miyata; K Taniguchi; T Seki; T Ishimoto; M Sato-Watanabe; Y Yasuda; M Doi; S Kametani; Y Tomishima; T Ueki; M Sato; K Kameo
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

2.  Contribution of Ras GTPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension.

Authors:  M M Muthalif; I F Benter; Z Khandekar; L Gaber; A Estes; S Malik; J H Parmentier; V Manne; K U Malik
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

3.  Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation.

Authors:  Austin M Guo; Ali S Arbab; John R Falck; Ping Chen; Paul A Edwards; Richard J Roman; A Guillermo Scicli
Journal:  J Pharmacol Exp Ther       Date:  2007-01-08       Impact factor: 4.030

4.  Changes in the expression of cytochromes P450 and nuclear receptors in the liver of genetically diabetic db/db mice.

Authors:  Kouichi Yoshinari; Shunsuke Takagi; Junko Sugatani; Masao Miwa
Journal:  Biol Pharm Bull       Date:  2006-08       Impact factor: 2.233

5.  The mechanism of phenylephrine-mediated [Ca(2+)](i) oscillations underlying tonic contraction in the rabbit inferior vena cava.

Authors:  C H Lee; D Poburko; P Sahota; J Sandhu; D O Ruehlmann; C van Breemen
Journal:  J Physiol       Date:  2001-08-01       Impact factor: 5.182

6.  Role of cGMP versus 20-HETE in the vasodilator response to nitric oxide in rat cerebral arteries.

Authors:  C W Sun; J R Falck; H Okamoto; D R Harder; R J Roman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-07       Impact factor: 4.733

7.  Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites.

Authors:  M M Muthalif; N A Karzoun; L Gaber; Z Khandekar; I F Benter; A E Saeed; J H Parmentier; A Estes; K U Malik
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

Review 8.  Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids.

Authors:  R J Roman; K G Maier; C W Sun; D R Harder; M Alonso-Galicia
Journal:  Clin Exp Pharmacol Physiol       Date:  2000-11       Impact factor: 2.557

9.  Angiotensin II releases 20-HETE from rat renal microvessels.

Authors:  K D Croft; J C McGiff; A Sanchez-Mendoza; M A Carroll
Journal:  Am J Physiol Renal Physiol       Date:  2000-09

10.  Contribution of both Ca2+ entry and Ca2+ sensitization to the alpha1-adrenergic vasoconstriction of rat penile small arteries.

Authors:  Nuria Villalba; Edgaras Stankevicius; Albino Garcia-Sacristán; Ulf Simonsen; Dolores Prieto
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-11-03       Impact factor: 4.733

View more
  11 in total

1.  Inhibition of 20-HETE attenuates diabetes-induced decreases in retinal hemodynamics.

Authors:  Zhongli Wang; Amit Singh Yadav; Wendy Leskova; Norman R Harris
Journal:  Exp Eye Res       Date:  2011-05-30       Impact factor: 3.467

2.  Mechanism of impaired afferent arteriole myogenic response in Dahl salt-sensitive rats: role of 20-HETE.

Authors:  YiLin Ren; Martin A D'Ambrosio; Jeffrey L Garvin; Edward L Peterson; Oscar A Carretero
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-02

3.  Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke.

Authors:  Anjana Munshi; Vandana Sharma; Subhash Kaul; Amal Al-Hazzani; Ali A Alshatwi; Gowhar Shafi; Rajeshwar Koppula; Sai Babu Mallemoggala; A Jyothy
Journal:  Mol Biol Rep       Date:  2011-05-31       Impact factor: 2.316

4.  20-HETE attenuates the response of glucose-stimulated insulin secretion through the AKT/GSK-3β/Glut2 pathway.

Authors:  Bijun Zhang; Guangrui Lai; Jingjing Wu; Ru Sun; Runhong Xu; Xianghong Yang; Yafei Qi; Yanyan Zhao
Journal:  Endocrine       Date:  2016-08-27       Impact factor: 3.633

5.  20-HETE induces hyperglycemia through the cAMP/PKA-PhK-GP pathway.

Authors:  Guangrui Lai; Jingjing Wu; Xiaoliang Liu; Yanyan Zhao
Journal:  Mol Endocrinol       Date:  2012-08-23

6.  20-Hydroxyeicosatetraenoic acid impairs endothelial insulin signaling by inducing phosphorylation of the insulin receptor substrate-1 at Ser616.

Authors:  Xuguang Li; Gang Zhao; Ben Ma; Rui Li; Jiang Hong; Shaowen Liu; Dao Wen Wang
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

Review 7.  Clinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain: An Emerging Therapeutic Target.

Authors:  Osama H Elshenawy; Sherif M Shoieb; Anwar Mohamed; Ayman O S El-Kadi
Journal:  Pharmaceutics       Date:  2017-02-20       Impact factor: 6.321

8.  11,12-Epoxyeicosatrienoic acid induces vasodilator response in the rat perfused mesenteric vasculature.

Authors:  S M Bihzad; M H M Yousif
Journal:  Auton Autacoid Pharmacol       Date:  2017-01

9.  Chronic treatment with Ang-(1-7) reverses abnormal reactivity in the corpus cavernosum and normalizes diabetes-induced changes in the protein levels of ACE, ACE2, ROCK1, ROCK2 and omega-hydroxylase in a rat model of type 1 diabetes.

Authors:  Mariam H M Yousif; Batoul Makki; Ahmed Z El-Hashim; Saghir Akhtar; Ibrahim F Benter
Journal:  J Diabetes Res       Date:  2014-09-16       Impact factor: 4.011

10.  20-HETE interferes with insulin signaling and contributes to obesity-driven insulin resistance.

Authors:  Ankit Gilani; Kevin Agostinucci; Sakib Hossain; Jonathan V Pascale; Victor Garcia; Adeniyi Michael Adebesin; John R Falck; Michal Laniado Schwartzman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2020-10-01       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.